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Venous access is the foundation for safe and effective
hospital-based care. Inpatient providers must have a deep
knowledge of the different types of venous access devices
(VADs), their relative indications, contraindications, and
appropriateness. However, such knowledge is difficult to
come by and usually only gleaned through years of clinical
experience. To bridge this gap, we provide an in-depth
summary of the relevant anatomical considerations, physi-
cal characteristics, advantages, and disadvantages of
VADs commonly used in the hospital setting. In doing so,
we seek to improve the safety and share the science of vas-
cular access with frontline clinicians. To aid decision-
making, we conclude by operationalizing the available data
through algorithms that outline appropriate vascular access
for the hospitalized patient. Journal of Hospital Medicine
2015;10:471–478.VC 2015 Society of Hospital Medicine
Reliable venous access is fundamental for the safe and
effective care of hospitalized patients. Venous access
devices (VADs) are conduits for this purpose, providing
delivery of intravenous medications, accurate measure-
ment of central venous pressure, or administration of
life-saving blood products. Despite this important role,
VADs are also often the source of hospital-acquired
complications. Although inpatient providers must bal-
ance the relative risks of VADs against their benefits,
the evidence supporting such decisions is often limited.
Advances in technology, scattered research, and growing
availability of novel devices has only further fragmented
provider knowledge in the field of vascular access.1
It is not surprising, then, that survey-based studies
of hospitalists reveal important knowledge gaps with
regard to practices associated with VADs.2 In this nar-
rative review, we seek to bridge this gap by providing
a concise and pragmatic overview of the fundamentals
of venous access. We focus specifically on parameters
that influence decisions regarding VAD placement in
hospitalized patients, providing key takeaways for
practicing hospitalists.
METHODS
To compile this review, we systematically searched
Medline (via Ovid) for several keywords, including:
peripheral intravenous catheters, ultrasound-guided
peripheral catheter, intraosseous, midline, peripherally
inserted central catheter, central venous catheters, and
vascular access device complications. We concentrated
on full-length articles in English only; no date restric-
tions were placed on the search. We reviewed guide-
lines and consensus statements (eg, from the Center
for Disease Control [CDC] or Choosing Wisely crite-
ria) as appropriate. Additional studies of interest were
identified through content experts (M.P., C.M.R.) and
bibliographies of included studies.
SCIENTIFIC PRINCIPLES UNDERPINNING
VENOUS ACCESS
It is useful to begin by reviewing VAD-related nomen-
clature and physiology. In the simplest sense, a VAD
consists of a hub (providing access to various connec-
tors), a hollow tube divided into 1 or many sections
(lumens), and a tip that may terminate within a cen-
tral or peripheral blood vessel. VADs are classified as
central venous catheters (eg, centrally inserted central
catheters [CICCs] or peripherally inserted central
catheters [PICCs]) or peripheral intravenous catheters
(eg, midlines or peripheral intravenous catheters)
based on site of entry and location of the catheter tip.
Therefore, VADs entering via proximal or distal veins
of the arm are often referred to as “peripheral lines,”
as their site of entry and tip both reside within periph-
eral veins. Conversely, the term “central line” is often
used when VADs enter or terminate in a central vein
(eg, subclavian vein insertion with the catheter tip in
the lower superior vena cava).
Attention to a host of clinical and theoretical
parameters is important when choosing a device for
venous access. Some such parameters are summarized
in Table 1.
VENOUS ACCESS DEVICES
We will organize our discussion of VADs based on
whether they terminate in peripheral or central
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vessels. These anatomical considerations are relevant
as they determine physical characteristics, compatibil-
ity with particular infusates, dwell time, and risk of
complications associated with each VAD discussed in
Table 2.
Peripheral Venous Access
Short Peripheral Intravenous Catheter
Approximately 200 million peripheral intravenous
catheters (PIVs) are placed annually in the United
States, making them the most common intravenous
catheter.3 PIVs are short devices, 3 to 6 cm in length,
that enter and terminate in peripheral veins (Figure
1A). Placement is recommended in forearm veins
rather than those of the hand, wrist, or upper arm, as
forearm sites are less prone to occlusion, accidental
removal, and phlebitis.4 Additionally, placement in
hand veins impedes activities of daily living (eg, hand
washing) and is not preferred by patients.5 PIV size
ranges from 24 gauge (smallest) to 14 gauge (largest);
larger catheters are often reserved for fluid resuscita-
tion or blood transfusion as they accommodate
greater flow and limit hemolysis. To decrease risk of
phlebitis and thrombosis, the shortest catheter
and smallest diameter should be used. However,
unless adequately secured, smaller diameter catheters
are also associated with greater rates of accidental
removal.4,5
By definition, PIVs are short-term devices. The
CDC currently recommends removal and replacement
of these devices no more frequently than every 72 to
96 hours in adults. However, a recent randomized
controlled trial found that replacing PIVs when clini-
cally indicated (eg, device failure, phlebitis) rather
than on a routine schedule added 30 hours to their
lifespan without an increase in complications.6 A sys-
tematic review by the Cochrane Collaboration echoes
TABLE 1. Important Considerations When Selecting
Vascular Access Devices
Parameter Major Considerations
Desired flow rate Smaller diameter veins susceptible to damage with high flow
rates.
Short, large-bore catheters facilitate rapid infusion.
Nature of infusion pH, viscosity, and temperature may damage vessels.
Vesicants and irritants should always be administered into
larger, central veins.
Desired duration of vascular
access, or “dwell time”
Vessel thrombosis or phlebitis increase over time with cathe-
ter in place.
Intermittent infusions increase complications in central cathe-
ters; often tunneled catheters are recommended.
Urgency of placement Access to large caliber vessels is often needed in
emergencies.
Critically ill or hemodynamically unstable patients may
require urgent access for invasive monitoring or rapid
infusions.
Patients with trauma often require large volumes of blood
products and reliable access to central veins.
Number of device lumens VADs may have single or multiple lumens.
Multilumen allows for multiple functions (eg, infusion of mul-
tiple agents, measurement of central venous pressures,
blood draws).
Device gauge In general, use of a smaller-gauge catheter is preferred to
prevent complications.
However, larger catheter diameter may be needed for spe-
cific clinical needs (eg, blood transfusion).
Device coating VADs may have antithrombotic or anti-infective coatings.
These devices may be of value in patients at high risk of
complications.
Such devices, however, may be more costly than their
counterparts.
Self-care compatibility VADs that can be cared for by patients are ideal for outpatient
care.
Conversely, VADs such as peripheral catheters, are highly
prone to dislodgement and should be reserved for super-
vised settings only.
NOTE: Abbreviations: VAD, vascular access device.
TABLE 2. Pathogenesis and Prevention of Common
VAD-Associated Complications
Complications Major Considerations
Infection VADs breach the integrity of skin and permit skin pathogens to enter the
blood stream (extraluminal infection).
Inadequate antisepsis of the VAD hub, including poor hand hygiene, fail-
ure to "scrub the hub," and multiple manipulations may also
increase the risk of VAD-related infection (endoluminal infection).
Infections may be local (eg, exit-site infections) or may spread hematog-
enously (eg, CLABSI).
Type of VAD, duration of therapy, and host characteristics interact to
influence infection risk.
VADs with antiseptic coatings (eg, chlorhexidine) or antibiotic coatings
(eg, minocycline) may reduce risk of infection in high-risk patients.
Antiseptic-impregnated dressings may reduce risk of extraluminal
infection.
Venous thrombosis VADs predispose to venous stasis and thrombosis.
Duration of VAD use, type and care of the VAD, and patient characteris-
tics affect risk of thromboembolism.
VAD tip position is a key determinant of venous thrombosis; central
VADs that do not terminate at the cavo-atrial junction should be
repositioned to reduce the risk of thrombosis.
Antithrombotic coated or eluting devices may reduce risk of thrombosis,
though definitive data are lacking.
Phlebitis Inflammation caused by damage to tunica media.18
3 types of phlebitis:
Chemical: due to irritation of media from the infusate.
Mechanical: VAD physically damages the vessel.
Infective: bacteria invade vein and inflame vessel wall.
Phlebitis may be limited by close attention to infusate compatibility with
peripheral veins, appropriate dilution, and prompt removal of cathe-
ters that show signs of inflammation.
Phlebitis may be prevented in PICCs by ensuring at least a 2:1 vein:cath-
eter ratio.
Extravasation Extravasation (also called infiltration) is defined as leakage of infusate
from intravascular to extravascular space.
Extravasation of vesicants/irritants is particularly worrisome.
May result in severe tissue injury, blistering, and tissue necrosis.11
VADs should be checked frequently for adequate flushing and position
prior to each infusion to minimize risk.
Any VAD with redness, swelling, and tenderness at the entry site or
problems with flushing should not be used without further examina-
tion and review of position.
NOTE: Abbreviations: CLABSI, central line-associated blood stream infection; PICCs, peripherally inserted
central catheters; VAD, vascular access device.
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these findings.3 These data have thus been incorpo-
rated into recommendations from the Infusion Nurses
Society (INS) and the National Health Service in the
United Kingdom.5,7 In hospitalized patients, this
approach is relevant, as it preserves venous access
sites, maximizes device dwell, and limits additional
PIV insertions. In turn, these differences may reduce
the need for invasive VADs such as PICCs. Further-
more, the projected 5-year savings from implementa-
tion of clinically indicated PIV removal policies is
US$300 million and 1 million health-worker hours in
the United States alone.4
PIVs offer many advantages. First, they are mini-
mally invasive and require little training to insert. Sec-
ond, they can be used for diverse indications in
patients requiring short-term (1 week) venous
access. Third, PIVs do not require imaging to ensure
correct placement; palpation of superficial veins is suf-
ficient. Fourth, PIVs exhibit a risk of bloodstream
infection that is about 40-fold lower than more inva-
sive, longer-dwelling VADs8 (0.06 bacteremia per
1000 catheter-days).
Despite these advantages, PIVs also have important
drawbacks. First, a quarter of all PIVs fail through
occlusion or accidental dislodgement.4 Infiltration,
extravasation, and hematoma formation are important
adverse events that may occur in such cases. Second,
thrombophlebitis (pain and redness at the insertion
site) is frequent, and may require device removal,
especially in patients with catheters 20 guage.9
Third, despite their relative safety, PIVs can cause
localized or hematogenous infection. Septic thrombo-
phlebitis (superficial thrombosis and bloodstream
infection) and catheter-related bloodstream infection,
though rare, have been reported with PIVs and may
lead to serious complications.8,10 In fact, some suggest
that the overall burden of bloodstream infection risk
posed by PIVs may be similar to that of CICCs given
the substantially greater number of devices used and
greater number of device days.8
PIVs and other peripheral VADs are not suitable for
infusion of vesicants or irritants, which require larger,
central veins for delivery. Vesicants (drugs that cause
blistering on infusion) include chemotherapeutic
FIG. 1. Illustrations of various vascular access devices. (A) Small peripheral intravenous. (B) Midline. (C) Peripherally inserted central catheter. (D) Nontunneled
centrally inserted central catheter (triple lumen displayed in this graphic). (E) Tunneled centrally inserted central catheter.
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agents (eg, dactinomycin, paclitaxel) and commonly
used nonchemotherapeutical agents (eg, diazepam,
piperacillin, vancomycin, esmolol, or total parenteral
nutrition [TPN]).11 Irritants (phlebitogenic drugs)
cause short-term inflammation and pain, and thus
should not be peripherally infused for prolonged dura-
tions. Common irritants in the hospital setting include
acyclovir, dobutamine, penicillin, and potassium
chloride.
Of note, about one-quarter of PIV insertions fail
owing to difficult intravenous access.12 Ultrasound-
guided peripheral intravenous (USGPIV) catheter
placement is emerging as a technique to provide
peripheral access for such patients to avoid placement
of central venous access devices. Novel, longer devices
(>8 cm) with built-in guide wires have been devel-
oped to increase placement success of USGPIVs. These
new designs provide easier access into deeper arm
veins (brachial or basilic) not otherwise accessible by
short PIVs. Although studies comparing the efficacy of
USGPIV devices to other VADs are limited, a recent
systematic review showed that time to successful can-
nulation was shorter, and fewer attempts were
required to place USGPIVs compared to PIVs.13 A
recent study in France found that USGPIVs met the
infusion needs of patients with difficult veins with
minimal increase in complications.14 Despite these
encouraging data, future studies are needed to better
evaluate this technology.
Midline Catheter
A midline is a VAD that is between 7.5 to 25 cm in
length and is typically inserted into veins above the
antecubital fossa. The catheter tip resides in a periph-
eral upper arm vein, often the basilic or cephalic vein,
terminating just short of the subclavian vein (Figure
1B). Midline-like devices were first developed in the
1950s and were initially used as an alternative to PIVs
because they were thought to allow longer dwell
times.15 However, because they were originally con-
structed with a fairly rigid material, infiltration,
mechanical phlebitis, and inflammation were common
and tempered enthusiasm for their use.15,16 Newer
midline devices obviate many of these problems and
are inserted by ultrasound guidance and modified Sel-
dinger technique.17 Despite these advances, data
regarding comparative efficacy are limited.
Midlines offer longer dwell times than standard
PIVs owing to termination in the larger diameter
basilic and brachial veins of the arm. Additionally,
owing to their length, midlines are less prone to dis-
lodgement. As they are inserted with greater antisepsis
than PIVs and better secured to the skin, they are
more durable than PIVs.5,9,18 Current INS standards
recommend use of midlines for 1 to 4 weeks.5 Because
they terminate in a peripheral vein, medications and
infusions compatible with midlines are identical to
those that are infused through a PIV. Thus, TPN,
vesicants or irritants, or drugs that feature a pH <5
or pH >9, or >500 mOsm should not be infused
through a midline.15 New evidence suggests that
diluted solutions of vancomycin (usually pH <5) may
be safe to infuse for short durations (<6 days)
through a midline, and that concentration rather than
pH may be more important in this regard.19 Although
it is possible that the use of midlines may extend to
agents typically not deemed peripheral access compati-
ble, limited evidence exists to support such a strategy
at this time.
Midlines offer several advantages. First, because
blood flow is greater in the more proximal veins of
the arm, midlines can accommodate infusions at rates
of 100 to 150 mL/min compared to 20 to 40 mL/min
in smaller peripheral veins. Higher flow rates offer
greater hemodilution (dilution of the infusion with
blood), decreasing the likelihood of phlebitis and infil-
tration.20 Second, midlines do not require x-ray verifi-
cation of tip placement; thus, their use is often
favored in resource-depleted settings such as skilled
nursing facilities. Third, midlines offer longer dwell
times than peripheral intravenous catheters and can
thus serve as “bridge” devices for short-term intrave-
nous antibiotics or peripheral-compatible infusions in
an outpatient setting. Available evidence suggests that
midlines are associated with low rates of bloodstream
infection (0.3–0.8 per 1000 catheter-days).17 The
most frequent complications include phlebitis (4.2%)
and occlusion (3.3%).20 Given these favorable statis-
tics, midlines may offer a good alternative to PIVs in
select patients who require peripheral infusions of
intermediate duration.
Intraosseous Vascular Access
Intraosseous (IO) devices access the vascular system
by piercing cortical bone. These devices provide access
to the intramedullary cavity and venous plexi of long
bones such as the tibia, femur, or humerus. Several
insertion devices are now commercially available and
have enhanced the ease and safety of IO placement.
Using these newer devices, IO access may be obtained
in 1 to 2 minutes with minimal training. By compari-
son, a central venous catheter often requires 10 to 15
minutes to insert with substantial training efforts for
providers.21–23
IO devices thus offer several advantages. First, given
the rapidity with which they can be inserted, they are
often preferred in emergency settings (eg, trauma).
Second, these devices are versatile and can accommo-
date both central and peripheral infusates.24 Third, a
recent meta-analysis found that IOs have a low com-
plication rate of 0.8%, with extravasation of infusate
through the cortical entry site being the most common
adverse event.21 Of note, this study also reported
zero local or distal infectious complications, a finding
that may relate to the shorter dwell of these devices.21
Some animal studies suggest that fat embolism from
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bone may occur at high rates with IO VADs.25 How-
ever, death or significant morbidity from fat emboli in
humans following IO access has not been described.
Whether such emboli occur or are clinically significant
in the context of IO devices remains unclear at
this time.21
Central Venous Access Devices
Central venous access devices (CVADs) share in com-
mon tip termination in the cavo-atrial junction, either
in the lower portion of the superior vena cava or in the
upper portion of the right atrium. CVADs can be safely
used for irritant or vesicant medications as well as for
blood withdrawal, blood exchange procedures (eg, dial-
ysis), and hemodynamic monitoring. Traditionally,
these devices are 15 to 25 cm in length and are directly
inserted in the deep veins of the supra- or infraclavicu-
lar area, including the internal jugular, brachiocephalic,
subclavian, or axillary veins. PICCs are unique CVADs
in that they enter through peripheral veins but termi-
nate in the proximity of the cavoatrial junction.
Regarding nomenclature, CICC will be used to denote
devices that enter directly into veins of the neck or
chest, whereas PICC will be used for devices that are
inserted peripherally but terminate centrally.
Peripherally Inserted Central Catheter
PICCs are inserted into peripheral veins of the upper
arm (eg, brachial, basilica, or cephalic vein) and
advanced such that the tip resides at the cavoatrial
junction (Figure 1C). PICCs offer prolonged dwell
times and are thus indicated when patients require
venous access for weeks or months.26 Additionally,
they can accommodate a variety of infusates and are
safer to insert than CICCs, given placement in periph-
eral veins of the arm rather than central veins of the
chest/neck. Thus, insertion complications such as pneu-
mothorax, hemothorax, or significant bleeding are rare
with PICCs. In fact, a recent study reported that PICC
insertion by hospitalists was associated with low rates
of insertion or infectious complications.27
However, like CICCs, PICCs are associated with
central line–associated bloodstream infection
(CLABSI), a serious complication known to prolong
length of hospital stay, increase costs, and carry a
12% to 25% associated mortality.28,29 In the United
States alone, over 250,000 CLASBI cases occur per
year drawing considerable attention from the CDC
and Joint Commission, who now mandate reporting
and nonpayment for hospital-acquired CLABSI.30–32
A recent systematic review and meta-analysis found
that PICCs are associated with a substantial risk of
CLABSI in hospitalized patients.33 Importantly, no
difference in CLABSI rates between PICCs and CICCs
in hospitalized patients was evident in this meta-
analysis. Therefore, current guidelines specifically rec-
ommend against use of PICCs over CICCs as a strat-
egy to reduce CLABSI.34 Additionally, PICCs are
associated with 2.5-fold greater risk of deep vein
thrombosis (DVT) compared to CICCs; thus, they
should be used with caution in patients with cancer or
those with underlying hypercoagulable states.
Of particular import to hospitalists is the fact that
PICC placement is contraindicated in patients with
FIG. 2. Algorithm for selection of vascular access. Abbreviations: CKD, chronic kidney disease; CVC, central venous catheter; IO, intraosseous; PICC, peripher-
ally inserted central catheter; PIV, peripheral intravenous; USGPIV, ultrasound-guided peripheral intravenous.
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stage IIIB or greater chronic kidney disease (CKD). In
such patients, sequelae of PICC use, such as phlebitis
or central vein stenosis, can be devastating in patients
with CKD.35 In a recent study, prior PICC placement
was the strongest predictor of subsequent arteriove-
nous graft failure.36 For this reason, Choosing Wisely
recommendations call for avoidance of PICCs in such
patients.37
Centrally Inserted Central Catheter
CICCs are CVADs placed by puncture and cannula-
tion of the internal jugular, subclavian, brachioce-
phalic, or femoral veins (Figure 1D) and compose the
vast majority of VADs placed in ICU settings.38,39
Central termination of CICCs allows for a variety of
infusions, including irritants, vesicants, and vasopres-
sors, as well as blood withdrawal and hemodynamic
monitoring. CICCs are typically used for 7 to 14
days, but may remain for longer durations if they
remain complication free and clinically necessary.40 A
key advantage of CICCs is that they can be placed in
emergent settings to facilitate quick access for rapid
infusion or hemodynamic monitoring. In particular,
CICCs are inserted in the femoral vein and may be
useful in emergency settings. However, owing to risk
of infection and inability to monitor central pressures,
these femoral devices should be replaced with a
proper CICC or PICC when possible. Importantly,
although CICCs are almost exclusively used in inten-
sive or emergency care, PICCs may also be considered
in such settings.41,42 CICCs usually have multiple
lumens and often serve several simultaneous functions
such as both infusions and hemodynamic monitoring.
Despite their benefits, CICCs have several disadvan-
tages. First, insertion requires an experienced clinician
and has historically been a task limited to physicians.
However, this is changing rapidly (especially in
Europe and Australia) where specially trained nurses
are assuming responsibility for CICC placement.43
Second, these devices are historically more likely to be
associated with CLABSI, with estimates of infection
rates varying between 2 and 5 infections per 1000
catheter-days.44 Third, CICCs pose a significant DVT
risk, with rates around 22 DVTs per 1000 catheter-
days.45 However, compared to PICCs, the DVT risk
appears lower, and CICC use may be preferable in
patients at high risk of DVT, such as critically ill or
cancer populations.46 An important note to prevent
CICC insertion complications relates to use of ultra-
sound, a practice that has been associated with
decreased accidental arterial puncture and hematoma
formation. The role of ultrasound guidance with
PICCs as well as implications for thrombotic and
infectious events remains less characterized at this
point.47
Tunneled Central Venous Access Devices
Tunneled devices (either CICCs or PICCs) are charac-
terized by the fact that the insertion site on the skin
and site of ultimate venipuncture are physically sepa-
rated (Figure 1E). Tunneling limits bacterial entry
from the extraluminal aspect of the CVAD to the
bloodstream. For example, internal jugular veins are
often ideal sites of puncture but inappropriate sites for
catheter placement, as providing care to this area is
challenging and may increase risk of infection.34
TABLE 3. Reference Table of Common Vascular Access Devices and Their Respective Usage Parameters
Vascular Access
Device
Central/
Peripheral
Anatomical Location
of Placement
Desired Duration
of Placement Common Uses
BSI Risk
(Per 1,000
Catheter-Days)
Thrombosis
Risk Important Considerations
Small peripheral IV Peripheral Peripheral veins, usually forearm 7–10 days Fluid resuscitation, most medications,
blood products
0.068 Virtually
no risk
Consider necessity of PIV daily
and remove unnecessary
devices
Midline Peripheral Inserted around antecubital fossa,
reside within basilic or cephalic
vein of the arm
2–4 weeks Long-term medications excluding
TPN, vesicants, corrosives
0.3–0.817 Insufficient
data
Can be used as bridge devices for
patients to complete short-
term antibiotics/infusions as
an outpatient
Peripherally inserted
central catheter
Central Inserted into peripheral arm vein and
advanced to larger veins (eg,
internal jugular or subclavian) to
the CAJ
>1 week,
<3 months
Large variety of infusates, including
TPN, vesicants, corrosives
2.444 6.30% Contraindicated in patients with
CKD stage IIIb or higher
Centrally inserted
central catheters
Central Inserted above (internal jugular vein,
brachiocephalic vein, subclavian
vein), or below the clavicle (axil-
lary vein)
>1 week,
<3 months
Same infusate variety as PICC, mea-
surement of central venous pres-
sures, common in trauma/
emergent settings
2.344 1.30% Given lower rates of DVT than
PICC, preferred in ICU and
hypercoagulable
environments
Tunneled CICCs Central Placed percutaneously in any large
vein in the arm, chest, neck or
groin
>3 months
to years
Central infusates, as in any CVAD;
used for patients with CKD stage
IIIb or greater when a PICC is
indicated
Insufficient
data
Insufficient
data
May be superior when insertion
site and puncture site are not
congruent and may increase
risk of infection
NOTE: Abbreviations: CAJ, cavoatrial junction; CICCs, centrally inserted central catheters; CKD, chronic kidney disease; CVAD, central vascular access device; DVT, deep vein thrombosis; ICU, intensive care unit; IV, intrave-
nous; PICC, peripherally inserted central catheter; PIV, peripheral IV; TPN, total parenteral nutrition.
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Tunneling to the infraclavicular area provides a better
option, as it provides an exit site that can be
adequately cared for. Importantly, any CVAD (PICCs
or CICCs) can be tunneled. Additionally, tunneled
CICCs may be used in patients with chronic or
impending renal failure where PICCs are contraindi-
cated because entry into dialysis-relevant vessels is to
be avoided.48 Such devices also allow regular blood
sampling in patients who require frequent testing but
have limited peripheral access, such as those with
hematological malignancies. Additionally, tunneled
catheters are more comfortable for patients and
viewed as being more socially acceptable than nontun-
neled devices. However, the more invasive and perma-
nent nature of these devices often requires
deliberation prior to insertion.
Of note, tunneled devices and ports may be used as
long-term (>3 months to years) VADs. As our focus
in this review is short-term devices, we will not
expand the discussion of these devices as they are
almost always used for prolonged durations.7
OPERATIONALIZING THE DATA: AN
ALGORITHMIC APPROACH TO VENOUS
ACCESS
Hospitalists should consider approaching venous
access using an algorithm based on a number of
parameters. For example, a critically ill patient who
requires vasopressor support and hemodynamic moni-
toring will need a CICC or a PICC. Given the poten-
tial greater risk of thromboses from PICCs, a CICC is
preferable for critically ill patients provided an experi-
enced inserter is available. Conversely, patients who
require short-term (<7–10 days) venous access for
infusion of nonirritant or nonvesicant therapy often
only require a PIV. In patients with poor or difficult
venous access, USGPIVs or midlines may be ideal and
preferred over short PIVs. Finally, patients who
require longer-term or home-based treatment may
benefit from early placement of a midline or a PICC,
depending again on the nature of the infusion, dura-
tion of treatment, and available venous access sites.
An algorithmic approach considering these parame-
ters is suggested in Figure 2, and a brief overview of the
devices and their considerations is shown in Table 3.
CONCLUSIONS
With strides in technology and progress in medicine,
hospitalists have access to an array of options for
venous access. However, every VAD has limitations
that can be easily overlooked in a perfunctory
decision-making process. The data presented in this
review thus provide a first step to improving safety in
this evolving science. Studies that further determine
appropriateness of VADs in hospitalized settings are
necessary. Only through such progressive scientific
enquiry will complication-free venous access be
realized.
Disclosure: Nothing to report.
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